The global cardiac biomarkers market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of cardiovascular diseases and increasing number of the geriatric population globally.
Cardiac biomarkers are types of proteins, which are released into the bloodstream from heart muscle. The biomarkers are released when the heart muscle is damaged due to a blocked artery. Cardiac biomarkers, as endogenous agents such as carbohydrates, hormones, and proteins, are released into the blood when the heart is weakened or nervous. They are mainly used to diagnose heart attacks, acute coronary syndrome (ACS), and other disorders including a lack of blood supply to the heart.
Troponin is one of the most widely adopted biomarkers for detecting heart injury among cardiac biomarker tests and troponin levels rise quickly after heart injury and remain up for up to two weeks. The test is done using a blood sample drawn from a vein in the hand or arm with a needle. The test, which takes several hours to complete, helps in the diagnosis of a heart attack. Cardiac biomarkers are used to stratify risk for a variety of cardiovascular disorders (CVDs) such as myocardial infraction, congestive heart failure, and acute coronary syndrome (ACS). CK-MB, troponin I and T, myoglobin, BNPs, IMA, and other cardiac biomarkers are commonly used in an integrated diagnostic approach for CVDs.
The report on the global cardiac biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Cardiac Biomarkers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Types (Troponin, Creatine kinase - MB, Natriuretic Peptides - B-type Natriuretic Peptide & N-terminal pro B-type Natriuretic Peptide, Myoglobin, Ischemia Modified Albumin, Heart-type Fatty Acid Binding Protein, and LDH Isoenzymes), Applications (Acute Coronary Syndrome, Myocardial infarction, Congestive Heart Failure, Cardiomyopathy, Ischemia, Myocarditis, and Atrial Fibrillation), and End-users (Laboratory Testing and Point of Care Testing) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., and Randox Laboratories Ltd. |
Troponin segment is expected to constitute a key share of the market
Based on types, the cardiac biomarkers market is segmented into troponin, creatine kinase - mb (CK-MB), natriuretic peptides - b-type natriuretic peptide (BNP) & n-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, ischemia modified albumin (IMA), heart-type fatty acid binding protein (H-FABP), LDH isoenzymes. The troponin segment is expected to constitute a key share of the market during the forecast period owing to their benefits in detecting AMI and their effectiveness in diagnosing cardiovascular diseases in a timely and reliable manner compared to other tests, which help in preventing adverse cardiac events. On the other hand, the natriuretic peptides segment is anticipated to expand at a rapid pace during the forecast period due to its efficiency in accurately diagnosing CHF.
Acute coronary syndrome segment is expected to hold a major market share
On the basis of applications, the market is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure, cardiomyopathy, ischemia, myocarditis, and atrial fibrillation. The acute coronary syndrome segment is expected to hold a major share of the market during the forecast period owing to a high rate of acute coronary syndrome. On the other hand, the myocardial infarction segment is anticipated to expand at a rapid pace during the forecast period owing to increasing geriatric population the prevalence of an obese & sedentary lifestyle among individuals, smoking & alcohol intake, and unhealthy eating patterns, all of which eventually contribute to obesity.
Point of care segment is expected to expand at a rapid pace
Based on end-users, the cardiac biomarkers market is bifurcated into laboratory testing and point of care (POC) testing. The POC testing segment is expected to account for a key share of the market during the forecast period owing to increasing demand for POC test kits. These kits are compact and convenient as they are easy to use, making them as common medical equipment in the home healthcare segment.
North America is anticipated to dominate the market
In terms of regions, the cardiac biomarkers market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to the high prevalence of coronary heart disease in the region as well as the wide popularity of point-of-care diagnostics, which have resulted in a substantial disease burden.
On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing population and rising prevalence of cardiovascular diseases in this region. The advent of the cardiac biomarkers vertical in the region is expected to be fueled by this rapid development.
Key players competing in the cardiac biomarkers market are Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., and Randox Laboratories Ltd.
These companies are constantly focusing on generating growth by creating innovative product designs and new tests as well as improving the specificity of the tests. Alere, Inc., for example, made the Alere triage line, which combines three important biomarkers: CK-MB, myoglobin, and troponin I. This test is easy to use and popular since it is a hybrid tool and an effective point-of-care cardiac testing package.
Key players competing in the cardiac biomarkers market are Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., and Randox Laboratories Ltd.
These companies are constantly focusing on generating growth by creating innovative product designs and new tests as well as improving the specificity of the tests. Alere, Inc., for example, made the Alere triage line, which combines three important biomarkers: CK-MB, myoglobin, and troponin I. This test is easy to use and popular since it is a hybrid tool and an effective point-of-care cardiac testing package.
Some other reports from this category!